PHLECS Blue LED Therapy Devices

The first Blue LED full-body, clinically proven platform to address
the unmet needs of patients with psoriasis conditions.

Phlecs leverages 15 years of clinical and technology research
originated at Philips Healthcare and offers a gentle, safe, clinically proven

Safe

Drug-Free

UV Free

Cost Effective

Our products utilize blue light in the 453nm wavelength range, which is visible to the human eye and contains no Ultraviolet (UV) radiation. The blue LED penetrates deep into the dermis of the skin, making it an effective and timely treatment for patients.

Our LEDs are specifically optimized for health and medical applications, providing clinical-grade intensities that ensure effective treatment.

Phlecs Blue LED Therapy – Full Body Professional

A UV-free, drug-free, Blue LED Therapy platform – Available for dermatology clinics in Europe

  • Medical Device CE Mark Class IIa
  • High-intensity, clinical-grade intensity, 453nm blue LEDs
  • Gentle and safe UV-free treatment
  • Easy handling for the operator with a single on/off button and an auto-timing treatment duration of 15 minutes per body side.
  • Can be self-administrated by patients
  • Relaxing experience for the patient due to the warm Blue LED Light during the treatment
  • No need for lamp replacement
  • Environmentally friendly: Mercury-free technology

Phlecs Blue LED Therapy – Full Body Home Connected

UV-free, drug-free, Blue LED Therapy for personalized at-home use

Launch 2028

  • Medical device to be CE marked Class IIa
  • Personalized treatment:
    • an algorithm adjusts key light parameters based on the patient’s condition
  • Easy to use
    • Portable and foldable
    • Self –administered
    • High patient compliance due to a relaxing and satisfying experience
  • Connected
    • Patient experience data is collected and adherence is monitored
    • Outcomes are shared with patients through an app
  • Environmentally friendly
    • Mercury-free technology

PHLECS offers a new drug-free, UV free treatment modality for patients and dermatologists.

This post is also available in: Dutch German